Xcur analyst. Smart Money. XCUR / INR Conversion Tables. Analyst Estimates; Options; Premium Tools; XCUR Overview 5 days ago · Billion Dollar Secret. Find the latest Insider Activity data for Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therap Chicago--(business wire)--exicure, inc. com. The price of Curate (XCUR) is $0. com - April 18 at 1:34 AM. , a private clinical stage biopharmaceutical company focused on viral and liver diseases CHICAGO, May 16, 2024--Exicure, Inc. 22. 00%) USD | NASDAQ | Jan 24, 16:00 Feb 5, 2024 · Exicure, Inc. 33 being its most recent. Add to Watchlist 0. 's performance made by these analysts are theirs alone and do not represent opinions, forecasts or 3 days ago · Virios Therapeutics (NASDAQ:VIRI – Get Free Report) and Exicure (NASDAQ:XCUR – Get Free Report) are both small-cap medical companies, but which is the superior investment?We will contrast the Dec 8, 2023 · XCUR stock is up 56. The company's proprietary spherical nucleic acid (SNA) technology is used to develop therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders. 30 Target First off, please don't take anything I been saying seriously or as financial advice. May 12, 2024 · Exicure, Inc. These XCUR analyst estimates including EPS estimates, revenue estimates and EBITDA estimates. About Us. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against Get the latest Exicure Inc (XCUR) stock analyst ratings and price targets from StockTargetAdvisor. Year-over-year quarterly sales growth most recently was %. XCUR has a higher number of analysts covering the stock than 31. Those same analysts give the stock an average rating of Hold. 2 mins . Shares Out 8. Q XCUR. Chart • Compare Perf. Ideas. This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data. 2 days ago · Get a real-time Exicure, Inc. That being said XCUR has a reasonable target of reaching $3. 98% of all US stocks. 3 days ago · Exicure Inc (XCUR) saw downtrend of -26. There are not analysts providing consensus earnings estimates for the current fiscal year. 00 expecting XCUR to rise to within 12 months (a possible 488. Aug 11, 2022 · InvestorsObserver is giving Exicure Inc (XCUR) an Analyst Rating Rank of 32, meaning XCUR is ranked higher by analysts than 32% of stocks. 34. 018 (-3. 88%) 14:09 EDT XCUR Stock Quote Delayed 30 Minutes. Discover historical prices for XCUR stock on Yahoo Finance. Jun 15, 2022 · InvestorsObserver is giving Exicure Inc (XCUR) an Analyst Rating Rank of 30, meaning XCUR is ranked higher by analysts than 30% of stocks. This means you can exchange 5 XCUR for $0. (XCUR) stock. Discover undervalued companies XCUR: Got Ways to Go $3. Industry Biotechnology. ET to 3:30 p. View real-time XCUR stock price and news, along with industry-best analysis. Search News & Quotes Topics Stock Picks Lists & Rankings Magazine Data Advisor Penta Exicure (NASDAQ: XCUR) just reported results for the third quarter of 2023. com - April 24 at 5:47 PM. Analyst Rating. Short Sale volume shows the number of trades marked as short sales in various trading venues. View Exicure, Inc. Wainwright. 30 soon in my opinion. 36 the company dropped to over past 52-weeks. The conversion rate of Curate (XCUR) to USD is $0. Nasdaq provides visual representation of analyst expected Trending. Get the latest Exicure, Inc XCUR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Exicure, Inc. Update Frequency: Daily at Close of Day Nov 15, 2022 · Price Action: XCUR shares are down 16. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. May 22, 2024 · Currently, Exicure Inc’s price-earnings ratio is 0. Intraday. 1 min . 78% over the next twelve months. Over. 53M, and at present, short sellers hold a 1. Analyst Ratings for Exicure Inc (XCUR) provide recommendations made by outside industry experts. ” The public float for XCUR is 7. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial Mar 27, 2023 · Exicure, Inc. North American Morning Briefing : Stocks Struggle After New Records. Nasdaq provides market information on after hours trading daily from 4:15 p. This widely-known consensus The Exicure Inc (XCUR) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $19. , a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc. Draw. Refer to our conversion tables for popular XCUR trading amounts in their corresponding INR prices and vice versa. 56 and a Piotroski F-Score of 5. 1 day ago · CI. Keay Nakae. (Nasdaq:XCUR) Historically, Exicure has been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K. View XCUR revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Analyst Ratings. businesswire. 00 and a low estimate of $ 0. (XCUR) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their Exicure has an Altman Z-Score of -17. The "Close/Last" is the “adjust consolidated close price”. off-exchange short sale volume is shown in the following chart. Make informed investment decisions with our expert insights. This represents a -1. (XCUR) stock price quote with breaking news, financials, statistics, charts and more. Refer to our conversion tables for popular XCUR trading amounts in their corresponding USD prices and vice versa. For more information on how to interpret this data, read this information notice provided by FINRA. 016 million. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on November 22 Story by InvestorPlace Earnings. 04% upside). Phone 1 847 673-1700. Chardan. Profitability This table compares Exicure and Virios XCUR Historical Data. Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company did not report View XCUR revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. 62% of all US stocks. The net and 52 Week Low Date 05/24/24. 5603 0. Daily. Email. . 6% profit margin. You can practice and explore trading XCUR stock methods without spending real money on the virtual paper trading platform. Apr 27, 2023 · Exicure, Inc. 00 . Dividend -. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company’s board of Mar 23, 2021 · The analyst adds that given the lead drug XCUR-FXN's pre-clinical data and the filing in 2021 to support clinical benefit, he sees a "compelling" risk-reward opportunity for Exicure. • now. 75 or ₹50. Average score: Sell. The average price target is $3. Our methodology considers analysis of the company's financial situation and how it has traded recently. 24% upside). will purchase an aggregate of 3,400,000 shares of common stock for an aggregate purchase price of $5. There are currently no analyst ratings available for Exicure. Our comprehensive analysis of fundamental and technical factors gives XCUR a rank of 6. The conversion rate of Curate (XCUR) to INR is ₹1. A Z-score under 3 suggests an increased risk of bankruptcy. 3. 02M. 1 min. Buy. View daily, weekly or monthly format back to when Exicure, Inc. investing. 28. is followed by the analysts listed above. Dec 22, 2021 · NEW YORK, NY / ACCESSWIRE / December 22, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Exicure, Inc. Date Range . Average price target from 1 ratings: $2. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for Exicure Inc (XCUR) $0. 01503 for every 1 XCUR. from DGP Co. Loading Chart for XCUR . Hold. Exicure (NASDAQ: XCUR) just reported results for the third quarter of 2023. 3% stake in Exicure, Inc. Get up to 10 years of daily historical stock prices & volumes. 448-0. Curate (XCUR) price has declined today. 00 for 37. C. ("Exicure" or the "Company Aug 4, 2021 · The market expects Exicure, Inc. Full Ratings. The company’s preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. 0. 00 (0. Analyst Estimates; Options; Premium Tools; XCUR Finanicals. ET) and the After Hours Market (4:00-8:00 p. Jul 8, 2021 · Exicure, Inc. But as Exicure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions. Beta 1. Headline. 8 million with a 13. CHICAGO, April 22, 2024--Exicure, Inc. (XCUR) stock, including valuation metrics, financial numbers, share information and more. 4 million, which would result in CBI obtaining a controlling stake in Exicure Exicure to reduce its workforce by approximately 66%, along with the implementation of other May 17, 2024 · By InvestorPlace Earnings May 16, 2024, 9:52 pm EDT. 50 marked by the stock while trading over the past 52-weeks, whereas it is -9. Participation from Market Makers and ECNs is strictly voluntary and as a result, these Sep 26, 2022 · Upon satisfaction of certain closing conditions including approval by Exicure stockholders, existing investor CBI USA, Inc. Top Holdings. 3300. -0. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. The event will showcase Exicure’s neuroscience pipeline, including its lead program for Friedreich’s Ataxia (FA), XCUR-FXN, which is designed to address the underlying molecular cause of FA The analyst firm set a price target for $2. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, David Giljohann , PhD, will present clinical data from the company’s Phase 1 study of its drug candidate XCUR17 in psoriasis. 10 Day Average Volume 0. 28. Find out what this means to you and get the rest of the rankings on XCUR! Apr 24, 2024 · Source. Feb 5, 2024 · Exicure, Inc. The current price level -78. Exicure Inc (XCUR) 0. An unknown buyer agreed to acquire 39. in september 2022, the company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the company was May 6, 2021 · The market expects Exicure, Inc. 6 days ago · A high-level overview of Exicure, Inc. 01 (1. The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Data provided by Edgar Online . 00 expecting XCUR to rise to within 12 months (a possible 304. Dividend Yield -. , a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. 27, representing a +3,679% increase from the current price of $0. 00. Here's a quick guide for how to read an earnings report. 125 and analyst’s rate the stock as a Buy. Apr 11, 2022 · Analysts who follow Exicure Inc on average expect it to add 1544. Apr 14, 2024 · Exicure Inc. analyst estimates, including XCUR earnings per share estimates and analyst recommendations. 04 XCUR, excluding fees. KNakae@chardan. XCUR rank of 6 means that it ranks below 94% of stocks. Revenue $28. Wall Street analysts are rating XCUR a Strong Buy today. This means you can exchange 5 XCUR for ₹6. (XCUR) is a clinical-stage biotechnology company with a market capitalization of $5. (XCUR) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2021. Analyst Rating Price 08/16/22 Chardan Capital Markets What this means: Exicure Inc. Q 5 days ago · The analyst firm set a price target for 2. Earnings Analyst Ratings Options Dividends IPOs. (XCUR) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2021. Feb. The average price target is $ 0. 68% of that float. 86%) Analyst Ratings. 74% over the next twelve months. 51% higher than the lowest price of $0. for KRW 6 billion. ,Ltd. 87% price decline in the past 7 days. 2, which means analysts expect the stock to add by 1677. Based on analysts offering 12 month price targets for XCUR in the last 3 months. (NASDAQ: XCUR), a pioneer in gene regulatory drugs utilizing spherical nucleic acid (SNA™) technology, will host a virtual RD Day on Thursday, July 15, 2021 from 10:00 am to 11:00 am ET. YTD % Change -43. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Exicure has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, July 12th, 2024 based off prior year's report dates. as well as how a company stacks up to analyst estimates. Visit the Earnings Calendar to see dates for upcoming earnings announcements. 65M. Search News & Quotes Topics Stock Picks Lists & Rankings Magazine Data Advisor Penta #RSLS - Why Ooma Shares Are Trading Higher By Around 17 Here Are 20 Stocks Moving Premarket Benzinga Shares of Ooma, Inc. It is still on a positive retracement wave looking at the entire chart history, and t Jan 5, 2021 · Exicure, Inc. A list of analyst ratings for Exicure (XCUR) stock. com - April 22 at 4:01 PM. 35 for every 1 XCUR. 00% lower than the highest price of $1. SEC Filings for Exicure Inc. rselvaraju@hcwco. Please note that any opinions, estimates or forecasts regarding Exicure, Inc. DJ. Fiscal Year-end 12/2023. In the context of all US stocks, EXICURE INC's upside potential (average analyst target price relative to current price) is greater than 935. Common Stock (XCUR) After-Hours Stock Quotes - Nasdaq offers The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. 05 during after-hours trading on Monday. 854M. Exicure's trailing price-to-earnings (PE) ratio of 0. 01475 today with a 24-hour trading volume of $343,597. 14, 2019- Exicure, Inc. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target? Analyst Forecast : Insufficient data to show price forecast. Per-Share Earnings, Actuals and Estimates. Data is currently not available. Nov 28, 2023 · CHICAGO, November 28, 2023--Exicure, Inc. 0 analyst firms have reported ratings in the last year. 4720. 7% at $1. Exicure faces Nasdaq non-compliance over delayed filing. That average ranking earns XCUR an Analyst Rating of 4, which is better than 4% of stocks based on data compiled by InvestorsObserver. 34%. Sector Health Care/Life Sciences. 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All . Investors looking for more of the most recent stock market stories are in the right place! We have all of the latest stock market news traders need to View XCUR fundamental and sentiment analysis powered by MarketGrader. (nasdaq: xcur), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Investors may trade in the Pre-Market (4:00-9:30 a. Technical Events. Market Cap 2. americanbankingnews. 6 days ago · Stock analysis for Exicure Inc (XCUR:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 42% Healthcare • Biotechnology • USA • NASD. " 6 days ago · Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of James Sulat to its Board of Directors. Participation from Market Makers and ECNs is Feb 25, 2022 · On average, analysts give XCUR a Hold rating. Oct 14, 2019 · Oct. -26. Mar. View the latest Exicure Inc. XCUR has a lower variance in analysts' estimates than -658. stock information by Barron's. James “Jim” Sulat joins Exicure after decades of experience advising and leading biopharmaceutical companies, including serving in the roles of President, Chief Executive Analyst Price Target for XCUR i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. historical stock charts and prices, analyst ratings, financials, and today’s real-time XCUR stock price. 33. (XCUR) gets a very poor rank from InvestorsObserver. Oct 16, 2019 · - XCUR17 clinical results announced in presentation at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich - - Clinical results presented show decrease in the levels of psoriasis and inflammation markers - Oct. Common Stock (XCUR) at Nasdaq. Candle - advanced. (XCUR) stock price, news, historical charts, analyst ratings and financial information from WSJ. XCUR stock quote prices, financial information, real-time forecasts, and company news from CNN. 328 indicates that the stock is undervalued compared to its Find the latest SEC Filings data for Exicure, Inc. 6 days ago · XCUR | Complete Exicure Inc. 83M. Reports Full Year 2022 Financial Results and Provides Corporate Update Business Wire - Mon Mar 27, 2023. 21, and the lowest is $21. Monthly. Source: iQoncept / Shutterstock. Under. 7%. 16, 2019- Exicure, Inc. , an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. May 22 • 01:17PM ET. 13. The average price target for XCUR is $93. 06 XCUR, excluding fees. XCUR - Exicure Inc - Stock screener for investors and traders, financial visualizations. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress. stock was issued. As always, this is on an opinion based basis. Exicure reported earnings per share of -61 cents. May 3, 2024 · Stay up-to-date on Exicure, Inc. The highest analyst price target is $17. Common Stock (XCUR) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. Net Aug 18, 2021 · That average ranking earns the stock an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver. Webull offers Exicure Inc (XCUR) historical stock prices, in-depth market analysis, NASDAQ: XCUR real-time stock quote data, in-depth charts. 00 with a high estimate of $ 0. Exicure Inc’s trailing 12-month revenue is $21. ET). Chicago, Illinois 60614. Corporate Update As previously reported, in September 2022, we announced a May 23, 2024 · NASDAQ: XCUR · IEX Real-Time Price · USD. The average price target for XCUR is $3. 843 and analyst’s rate the stock as a Buy. 47 0. 5397 (-3. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs May 26, 2023 · Exicure, Inc. Claim your free seat by clicking here now. Exicure (NASDAQ:XCUR) Shares Down 8. With a circulating supply of 50 Million XCUR, Curate is valued at a market cap of $737,343 . Personal Finance. Exicure Inc. 00 for 3326. 80%) Exicure, Inc. Income Statement; Balance Sheet; Cash Flow; Sec Filings; SHOW ALL 8-K 10-K 10-Q PROXY REGISTRATION 13D 13F 13G. The presentation, titled “Clinical Results from XCUR17, a Topically Applied XCUR / Exicure, Inc. Exicure reported earnings per Apr 26, 2024 · Complete Exicure Inc. The latest Exicure stock prices, stock quotes, news, and XCUR history to help you invest and trade smarter. View real-time stock prices and stock quotes for a full financial overview. and Bluejay Therapeutics Inc. XCUR / USD Conversion Tables. m. • Revenue • Dividends • Options • Save to Portfolio • Create Alert. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. (XCUR) with real-time updates, full price history, technical analysis and more. See the company profile for Exicure, Inc. 3 days ago · Exicure (NASDAQ:XCUR – Get Free Report) and Virios Therapeutics (NASDAQ:VIRI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Weekly. 98% of them. 2 days ago · The 36-month beta value for XCUR is also noteworthy at 1. 51. $ Market cap P/E ratio $ Price 1d change 52-week range. XCUR : 0. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis. CI. H. 7% as of Friday morning. Detailed statistics for Exicure, Inc. 0020 -0. 075164 or $50. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell. (NYSE:OOMA) rose sharply in today's pre-market trading after the company Term Box: Best Exicure Inc forecast, XCUR stock price prediction, XCUR forecast, Exicure Inc finance tips, XCUR prediction, Exicure Inc analyst report, XCUR stock price predictions 2023, Exicure Inc stock forecast, XCUR forecast tomorrow, Exicure Inc technical analysis, XCUR stock future price, Exicure Inc projections, Exicure Inc market prognosis, XCUR expected stock price. , (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc. 2430 North Halsted Street. stock news by MarketWatch. 34% in the recent trading with $0. ("Bluejay") and Exicure, Inc. Raghuram Selvaraju. That average rating earns XCUR an Analyst Ranking of 4, which means it ranks higher than 4 of stocks, based on data compiled by InvestorsObserver. Mar 28, 2024 · Interactive stock price chart for Exicure, Inc. View Exicure, Inc XCUR investment & stock information. 61% price decline in the last 24 hours and a -10. ET on the following day. 6 days ago · XCUR Competitors. 3 mins . cv bf oa mp vb ai ct kx mx dv